(Gastric Cancer) Is Enhertu Effective?
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
- November 24, 2022
- Reading time: 1 minute
On November 15, 2022, Kensei Yamaguchi and colleagues from Cancer Institute Hospital published results in the Journal of Clinical Oncology from the DESTINY-Gastric01 Phase II clinical trial evaluating Enhertu (trastuzumab deruxtecan) in HER2-positive advanced gastric cancer or gastroesophageal junction (GEJ) cancer patients with two or more prior lines of therapy.
The DESTINY-Gastric01 Phase II trial was a multicenter open-label study that randomized HER2-positive advanced gastric cancer or GEJ cancer patients with ≥2 prior lines of therapy in a 2:1 ratio to the Enhertu arm (6.4 mg/kg every 3 weeks) or chemotherapy arm. Primary endpoint was objective response rate (ORR); secondary endpoints included disease control rate, progression-free survival (PFS), and overall survival (OS). Patients were classified into cohort 1 (N=21) and cohort 2 (N=24) based on HER2 classification.
Results:
ORR: cohort 1 26.3% / cohort 2 9.5%. Tumor shrinkage rate: cohort 1 68.4% (N=13) / cohort 2 60.0% (N=12).
Median OS: cohort 1 7.8 months / cohort 2 8.5 months. Median PFS: cohort 1 4.4 months / cohort 2 2.8 months.
Safety:
Grade ≥3 adverse events included anemia (cohort 1: 30.0% / cohort 2: 29.2%), neutropenia (cohort 1: 25.0% / cohort 2: 29.2%), and decreased appetite (cohort 1: 20.0% / cohort 2: 20.8%). Drug-induced interstitial lung disease was confirmed in one patient per cohort.
Based on the DESTINY-Gastric01 trial results, Kensei Yamaguchi and colleagues concluded that Enhertu demonstrated clinically meaningful antitumor activity in HER2-positive advanced gastric cancer or GEJ cancer patients with ≥2 prior lines of therapy.
Source: https://ascopubs.org/doi/full/10.1200/JCO.22.00575
- Clinical trial drugs
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4